{"id":"gm1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2303685","moleculeType":"Small molecule","molecularWeight":"739.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GM1 ganglioside is an endogenous glycosphingolipid that acts as a neurotrophic factor, facilitating neuronal survival, differentiation, and synaptic plasticity. It modulates growth factor receptor signaling pathways and reduces inflammatory cytokine production in the central and peripheral nervous systems, thereby protecting neurons from degeneration and promoting functional recovery.","oneSentence":"GM1 is a monosialotetrahexosylganglioside that promotes neuronal protection and regeneration by enhancing nerve growth factor signaling and reducing neuroinflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:06.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Spinal cord injury"},{"name":"Peripheral nerve injury"}]},"trialDetails":[{"nctId":"NCT00029965","phase":"","title":"Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2002-02-06","conditions":"Neurological Regression, Myoclonus, Cherry Red Spot","enrollment":200},{"nctId":"NCT07479953","phase":"PHASE1","title":"A Phase I Study of Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"NOT_YET_RECRUITING","sponsor":"Tippi Mackenzie","startDate":"2026-06-01","conditions":"GM1 Gangliosidoses, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2","enrollment":5},{"nctId":"NCT00668187","phase":"","title":"A Natural History Study of the Gangliosidoses","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2010-12","conditions":"Tay-Sachs Disease, Sandhoff Disease, Late Onset Tay-Sachs Disease","enrollment":52},{"nctId":"NCT07082543","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Gangliosidoses, GM2, Gangliosidosis, GM1","enrollment":75},{"nctId":"NCT07082725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Niemann-Pick Type C Disease","enrollment":72},{"nctId":"NCT07054515","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis","enrollment":147},{"nctId":"NCT06773910","phase":"PHASE2","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-03-11","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":250},{"nctId":"NCT05751668","phase":"PHASE2","title":"Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-11-02","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma","enrollment":98},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT04041102","phase":"","title":"Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-06-12","conditions":"GM1 Gangliosidosis","enrollment":31},{"nctId":"NCT04702880","phase":"PHASE2","title":"A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-17","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT05109793","phase":"","title":"GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)","status":"COMPLETED","sponsor":"Azafaros A.G.","startDate":"2022-02-22","conditions":"GM1 Gangliosidosis, Sandhoff Disease, Tay-Sachs Disease","enrollment":31},{"nctId":"NCT06799286","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-07","conditions":"Small Cell Lung Carcinoma","enrollment":10},{"nctId":"NCT06994507","phase":"PHASE3","title":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-08-01","conditions":"Chemotherapy-induced Peripheral Neuropathy (CIPN)","enrollment":352},{"nctId":"NCT04713475","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gemma Biotherapeutics","startDate":"2021-03-17","conditions":"GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2","enrollment":26},{"nctId":"NCT05433181","phase":"PHASE1, PHASE2","title":"ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2025-02","conditions":"SARS-CoV-2","enrollment":""},{"nctId":"NCT06742216","phase":"PHASE3","title":"Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-03","conditions":"Acute Ischemic Stroke","enrollment":1232},{"nctId":"NCT04395339","phase":"PHASE3","title":"GM1 Prophylaxis for WBRT Related Cognitive Dysfunction","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2020-05-15","conditions":"Brain Metastases, Radiotherapy Side Effect, Cognitive Impairment","enrollment":51},{"nctId":"NCT05239663","phase":"PHASE3","title":"GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-02-08","conditions":"Chemotherapy-Related Cognitive Impairment, Breast Cancer","enrollment":76},{"nctId":"NCT06431971","phase":"PHASE2","title":"Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease","status":"NOT_YET_RECRUITING","sponsor":"InnoMedica Schweiz AG","startDate":"2024-08","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT04976127","phase":"PHASE1","title":"Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"InnoMedica Schweiz AG","startDate":"2021-12-07","conditions":"Parkinson Disease","enrollment":22},{"nctId":"NCT02247349","phase":"PHASE1, PHASE2","title":"BMS-986012 in Relapsed/Refractory SCLC","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-11-14","conditions":"Small Cell Lung Cancer","enrollment":106},{"nctId":"NCT04222790","phase":"PHASE2","title":"A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-08-28","conditions":"Early Breast Cancer","enrollment":159},{"nctId":"NCT04273269","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis","status":"TERMINATED","sponsor":"LYSOGENE","startDate":"2021-05-11","conditions":"GM1 Gangliosidosis","enrollment":5},{"nctId":"NCT04310163","phase":"","title":"Interviews and Video Capture in Patients With GM1 Gangliosidosis","status":"COMPLETED","sponsor":"LYSOGENE","startDate":"2020-04-20","conditions":"GM1 Gangliosidosis","enrollment":25},{"nctId":"NCT05802342","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-04-20","conditions":"To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients","enrollment":150},{"nctId":"NCT02298647","phase":"","title":"Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)","status":"WITHDRAWN","sponsor":"CENTOGENE GmbH Rostock","startDate":"2018-08-20","conditions":"Hepato-splenomegaly, Dysostosis Multiplex, Seizures","enrollment":""},{"nctId":"NCT04538833","phase":"PHASE2","title":"GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2020-09-09","conditions":"Early Breast Cancer","enrollment":""},{"nctId":"NCT04952064","phase":"PHASE4","title":"An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2021-07-28","conditions":"Stroke, Ischemic","enrollment":300},{"nctId":"NCT03556800","phase":"PHASE1","title":"Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.","status":"UNKNOWN","sponsor":"Viramal Limited","startDate":"2018-05-22","conditions":"Menopause","enrollment":20},{"nctId":"NCT04470713","phase":"","title":"Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-07-31","conditions":"GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2","enrollment":226},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT02030015","phase":"PHASE4","title":"Synergistic Enteral Regimen for Treatment of the Gangliosidoses","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-12-22","conditions":"GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease","enrollment":16},{"nctId":"NCT04624789","phase":"","title":"Registry Gangliosidoses","status":"UNKNOWN","sponsor":"SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)","startDate":"2020-06-08","conditions":"Gangliosidoses, GM1 Gangliosidosis, Morquio B Disease","enrollment":40},{"nctId":"NCT04320329","phase":"","title":"Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2020-06-01","conditions":"Morquio B Disease, GM1 Gangliosidosis Type III","enrollment":30},{"nctId":"NCT02104479","phase":"","title":"Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2014-03-31","conditions":"Invasive Aspergillosis, Pleural Effusion, Immunosuppression","enrollment":200},{"nctId":"NCT02251977","phase":"PHASE3","title":"Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2014-09","conditions":"Colorectal Cancer, Chemotherapy-induced Neutropenia","enrollment":196},{"nctId":"NCT00383448","phase":"PHASE2","title":"HSCT for High Risk Inherited Inborn Errors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-09","conditions":"Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy","enrollment":38},{"nctId":"NCT02486198","phase":"PHASE3","title":"Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2015-05-05","conditions":"Neurotoxicity","enrollment":145},{"nctId":"NCT01626092","phase":"NA","title":"Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-07-11","conditions":"Lysosomal Storage Disease, Peroxisomal Disorder","enrollment":3},{"nctId":"NCT01882621","phase":"PHASE3","title":"Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-10","conditions":"Non-small Cell Lung Cancer","enrollment":300},{"nctId":"NCT01349647","phase":"PHASE1","title":"Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-05","conditions":"Lung Cancer","enrollment":21},{"nctId":"NCT02024412","phase":"PHASE3","title":"Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2013-11","conditions":"Colorectal Cancer","enrollment":240},{"nctId":"NCT02024438","phase":"PHASE3","title":"Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2013-12","conditions":"Gastric Cancer","enrollment":240},{"nctId":"NCT02500810","phase":"PHASE2","title":"Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2015-07","conditions":"Neurotoxicity","enrollment":106},{"nctId":"NCT02093910","phase":"PHASE2","title":"Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT00654433","phase":"PHASE3","title":"ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases","status":"TERMINATED","sponsor":"Aldagen","startDate":"2008-03","conditions":"Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases","enrollment":40},{"nctId":"NCT01884987","phase":"","title":"Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2012-01","conditions":"Radiotherapy, Nasopharyngeal Carcinoma, Cerebral Radiation Necrosis","enrollment":30},{"nctId":"NCT00037830","phase":"PHASE2","title":"GM1 Ganglioside Effects on Parkinson's Disease","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"1999-11","conditions":"Parkinson Disease","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8831,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["monosialotetrahexosylganglioside"],"phase":"phase_3","status":"active","brandName":"GM1","genericName":"GM1","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GM1 is a monosialotetrahexosylganglioside that promotes neuronal protection and regeneration by enhancing nerve growth factor signaling and reducing neuroinflammation. Used for Acute ischemic stroke, Spinal cord injury, Peripheral nerve injury.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}